Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

27 Mar 2012

TB R&D Update: 243rd American Chemistry Society Conference

acs-logo

The 243rd American Chemistry Society National Meeting and Exposition is being held in San Diego, California, from March 26 to March 29. There are several presentations on tuberculosis. Here are the abstracts of a few of the talks. The first item received news coverage and discusses two approved antibiotics that may prove effective in treating TB. Additional links to TB R&D News are included.

23 Mar 2012
by Working Group

Posted in Action, Announcements, Events, TB News

World TB Day! Overview of Events, News and Messages

wtd2012

Saturday, March 24, is officially World TB Day but there has been a stream of activities, publications, news and messages to let the world not forget about this major infectious disease killer that claims millions of lives each year. We present links and summaries of events, publications, messages, and news coverage leading up to World TB Day.

21 Mar 2012
by Working Group

Posted in Announcements, Events, TB Drug Development, TB News

World TB Day Coverage: New Combo TB Drug Trial Announced

img_0842

During the “Cure All: A briefing on the status of the most promising new TB drugs research” sponsored by the Critical Path to New TB Drug Regimens (CPTR) on Monday, March 19, Dr. Mel Spigelman, CEO & President, of TB Alliance announced the launch of the NC002 trial, a combination drug trial that establishes a new pathway to TB and multi-drug resistant TB treatment. The meeting also involved high-level officials from U.S. agencies that support TB research including Anthony Fauci (Director, NIAID/NIH), Janet Woodcock (Director, CDER/FDA), and Robert Clay (Deputy Assistant Administrator, Global Health Bureau/USAID).

27 Jan 2012
by Working Group

Posted in Announcements, Events, TB Drug Development, TB News

Summary Available! TB Clinical Trials Consultants Meeting

Businesswoman Talking During Meeting

On November 17 and 18, a TB Clinical Trials Consultants Meeting was held at St. George’s, University of London. The meeting was organized by CDC, CPTR, INTERTB, NIH, and TB Alliance. The meeting was convened to catalog expert opinion on the conduct of Phase 2 and Phase 3 clinical trials in tuberculosis.

2 Nov 2011
by Working Group

Posted in Announcements, TB Drug Development, TB News

TB R&D Weekly Update: Progress in Development of New TB Drugs

WGND2011

During last week, the Stop TB Partnership Working Group on New Drugs had a successful annual meeting in Lille, France, in conjunction with the 42nd Union World Conference. There were quite a few updates to the Global TB Drugs Pipeline showing progress toward the goal of better treatment for TB in all patient populations. Additional links to TB R&D news are included.

20 Sep 2011

TB R&D Weekly Update: Zinc Used by Host to Fight TB

CHM_covhighres

This week, we provide an brief overview of research supported by CNRS, INSERM, Institut Pasteur and other donors providing new evidence of the role of Zinc in the body’s immune response to intracellular infection by M.tb. and the microbe’s strategy to subvert this defense. Additional links to TB R&D news are included.

8 Sep 2011

TB R&D Weekly Update: TB Drug Updates in Future Medicinal Chemistry

fmccover

Last week we posted information about two special issues of Future Medicinal Chemistry focused on neglected diseases. Future Medicinal Chemistry (September 2011, Volume 3, Number 11) have a few articles on tuberculosis drug development. Additional links to TB R&D news are included.

30 Aug 2011
by Working Group

Posted in Front Lines of TB R&D, TB News

TB R&D Weekly Update: Future Medicinal Chemistry Features Neglected Diseases

fmccover

The August and September issues of Future Medicinal Chemistry will focus on neglected diseases including tuberculosis. The issue includes articles from TB researchers including Ann Ginsberg and Takushi Kaneko. Additional links to TB R&D news are included

Private TB Drug Market is Larger than Expected

william wells

The first detailed study of the private tuberculosis (TB) drug market, published on May 4th, in the PLoS ONE journal, finds that the market is surprisingly large, and has irregular practices that could be driving treatment failures and contributing to the emergence of multidrug-resistant TB (MDR-TB).

First Chinese Product Development Partnership for TB, Malaria and HIV/AIDS Announced

partner

Today on World TB Day, the International Scientific Exchange Foundation of China (ISEFC), announced the signing of a Memorandum of Understanding with the Global Alliance for TB Drug Development (TB Alliance) to establish the Global Health R&D Center of China (GHRC). This innovative center will focus on the development of treatments for the world’s leading infectious disease killers—tuberculosis, malaria, and HIV/AIDS.